Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Single-Fraction Compared With Multiple-Fraction Therapy in Treating Patients With Previously Irradiated Painful Bone Metastases
A Phase III International Randomized Trial Of Single Versus Multiple Fractions For Re-Irradiation Of Painful Bone Metastases
Status: Archived
Gundersen Lutheran Center for Cancer and Blood
mi
from
La Crosse, WI
Single-Fraction Compared With Multiple-Fraction Therapy in Treating Patients With Previously Irradiated Painful Bone Metastases
A Phase III International Randomized Trial Of Single Versus Multiple Fractions For Re-Irradiation Of Painful Bone Metastases
Status: Archived
Updated: 1/1/1970
Gundersen Lutheran Center for Cancer and Blood
mi
from
La Crosse, WI
Single-Fraction Compared With Multiple-Fraction Therapy in Treating Patients With Previously Irradiated Painful Bone Metastases
A Phase III International Randomized Trial Of Single Versus Multiple Fractions For Re-Irradiation Of Painful Bone Metastases
Status: Archived
Aurora Sinai Medical Center / St. Lukes Medical Center
mi
from
Milwaukee, WI
Single-Fraction Compared With Multiple-Fraction Therapy in Treating Patients With Previously Irradiated Painful Bone Metastases
A Phase III International Randomized Trial Of Single Versus Multiple Fractions For Re-Irradiation Of Painful Bone Metastases
Status: Archived
Updated: 1/1/1970
Aurora Sinai Medical Center / St. Lukes Medical Center
mi
from
Milwaukee, WI
Single-Fraction Compared With Multiple-Fraction Therapy in Treating Patients With Previously Irradiated Painful Bone Metastases
A Phase III International Randomized Trial Of Single Versus Multiple Fractions For Re-Irradiation Of Painful Bone Metastases
Status: Archived
West Allis Memorial Hospital
mi
from
West Allis, WI
Single-Fraction Compared With Multiple-Fraction Therapy in Treating Patients With Previously Irradiated Painful Bone Metastases
A Phase III International Randomized Trial Of Single Versus Multiple Fractions For Re-Irradiation Of Painful Bone Metastases
Status: Archived
Updated: 1/1/1970
West Allis Memorial Hospital
mi
from
West Allis, WI
T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies
T-Cell Depleted, Reduced-Intensity Allogeneic Stem Cell Transplantation From Haploidentical Related Donors For Hematologic Malignancies
Status: Archived
National Cancer Institute (NCI)
mi
from
Bethesda, MD
T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies
T-Cell Depleted, Reduced-Intensity Allogeneic Stem Cell Transplantation From Haploidentical Related Donors For Hematologic Malignancies
Status: Archived
Updated: 1/1/1970
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Replagal Enzyme Replacement Therapy for Children With Fabry Disease
An Open Label Clinical Trial of Replagal Enzyme Replacement Therapy In Children With Fabry Disease Who Have Completed Study TKT023 or Who Are Naive to Enzyme Replacement Therapy
Status: Archived
University of Arizona College of Medicine
mi
from
Tucson, AZ
Replagal Enzyme Replacement Therapy for Children With Fabry Disease
An Open Label Clinical Trial of Replagal Enzyme Replacement Therapy In Children With Fabry Disease Who Have Completed Study TKT023 or Who Are Naive to Enzyme Replacement Therapy
Status: Archived
Updated: 1/1/1970
University of Arizona College of Medicine
mi
from
Tucson, AZ
Replagal Enzyme Replacement Therapy for Children With Fabry Disease
An Open Label Clinical Trial of Replagal Enzyme Replacement Therapy In Children With Fabry Disease Who Have Completed Study TKT023 or Who Are Naive to Enzyme Replacement Therapy
Status: Archived
Tucson Access Center of Arizona Kidney Disease Hypertension Center
mi
from
Tucson, AZ
Replagal Enzyme Replacement Therapy for Children With Fabry Disease
An Open Label Clinical Trial of Replagal Enzyme Replacement Therapy In Children With Fabry Disease Who Have Completed Study TKT023 or Who Are Naive to Enzyme Replacement Therapy
Status: Archived
Updated: 1/1/1970
Tucson Access Center of Arizona Kidney Disease Hypertension Center
mi
from
Tucson, AZ
Replagal Enzyme Replacement Therapy for Children With Fabry Disease
An Open Label Clinical Trial of Replagal Enzyme Replacement Therapy In Children With Fabry Disease Who Have Completed Study TKT023 or Who Are Naive to Enzyme Replacement Therapy
Status: Archived
Children's Nutrition Research Center, Baylor College of Medicine
mi
from
Houston, TX
Replagal Enzyme Replacement Therapy for Children With Fabry Disease
An Open Label Clinical Trial of Replagal Enzyme Replacement Therapy In Children With Fabry Disease Who Have Completed Study TKT023 or Who Are Naive to Enzyme Replacement Therapy
Status: Archived
Updated: 1/1/1970
Children's Nutrition Research Center, Baylor College of Medicine
mi
from
Houston, TX
Replagal Enzyme Replacement Therapy for Children With Fabry Disease
An Open Label Clinical Trial of Replagal Enzyme Replacement Therapy In Children With Fabry Disease Who Have Completed Study TKT023 or Who Are Naive to Enzyme Replacement Therapy
Status: Archived
Christus St. Patrick's Hospital
mi
from
Lake Charles, LA
Replagal Enzyme Replacement Therapy for Children With Fabry Disease
An Open Label Clinical Trial of Replagal Enzyme Replacement Therapy In Children With Fabry Disease Who Have Completed Study TKT023 or Who Are Naive to Enzyme Replacement Therapy
Status: Archived
Updated: 1/1/1970
Christus St. Patrick's Hospital
mi
from
Lake Charles, LA
Replagal Enzyme Replacement Therapy for Children With Fabry Disease
An Open Label Clinical Trial of Replagal Enzyme Replacement Therapy In Children With Fabry Disease Who Have Completed Study TKT023 or Who Are Naive to Enzyme Replacement Therapy
Status: Archived
St.Louis Children's Hospital
mi
from
St. Louis, MO
Replagal Enzyme Replacement Therapy for Children With Fabry Disease
An Open Label Clinical Trial of Replagal Enzyme Replacement Therapy In Children With Fabry Disease Who Have Completed Study TKT023 or Who Are Naive to Enzyme Replacement Therapy
Status: Archived
Updated: 1/1/1970
St.Louis Children's Hospital
mi
from
St. Louis, MO
Replagal Enzyme Replacement Therapy for Children With Fabry Disease
An Open Label Clinical Trial of Replagal Enzyme Replacement Therapy In Children With Fabry Disease Who Have Completed Study TKT023 or Who Are Naive to Enzyme Replacement Therapy
Status: Archived
New York University Langone Medical Center
mi
from
New York, NY
Replagal Enzyme Replacement Therapy for Children With Fabry Disease
An Open Label Clinical Trial of Replagal Enzyme Replacement Therapy In Children With Fabry Disease Who Have Completed Study TKT023 or Who Are Naive to Enzyme Replacement Therapy
Status: Archived
Updated: 1/1/1970
New York University Langone Medical Center
mi
from
New York, NY
Replagal Enzyme Replacement Therapy for Children With Fabry Disease
An Open Label Clinical Trial of Replagal Enzyme Replacement Therapy In Children With Fabry Disease Who Have Completed Study TKT023 or Who Are Naive to Enzyme Replacement Therapy
Status: Archived
Sacred Heart Hospital
mi
from
Allentown, PA
Replagal Enzyme Replacement Therapy for Children With Fabry Disease
An Open Label Clinical Trial of Replagal Enzyme Replacement Therapy In Children With Fabry Disease Who Have Completed Study TKT023 or Who Are Naive to Enzyme Replacement Therapy
Status: Archived
Updated: 1/1/1970
Sacred Heart Hospital
mi
from
Allentown, PA
Replagal Enzyme Replacement Therapy for Children With Fabry Disease
An Open Label Clinical Trial of Replagal Enzyme Replacement Therapy In Children With Fabry Disease Who Have Completed Study TKT023 or Who Are Naive to Enzyme Replacement Therapy
Status: Archived
East Tennessee Children's Hospital
mi
from
Knoxville, TN
Replagal Enzyme Replacement Therapy for Children With Fabry Disease
An Open Label Clinical Trial of Replagal Enzyme Replacement Therapy In Children With Fabry Disease Who Have Completed Study TKT023 or Who Are Naive to Enzyme Replacement Therapy
Status: Archived
Updated: 1/1/1970
East Tennessee Children's Hospital
mi
from
Knoxville, TN
Replagal Enzyme Replacement Therapy for Children With Fabry Disease
An Open Label Clinical Trial of Replagal Enzyme Replacement Therapy In Children With Fabry Disease Who Have Completed Study TKT023 or Who Are Naive to Enzyme Replacement Therapy
Status: Archived
Baylor Institute for Rehabilitation
mi
from
Dallas, TX
Replagal Enzyme Replacement Therapy for Children With Fabry Disease
An Open Label Clinical Trial of Replagal Enzyme Replacement Therapy In Children With Fabry Disease Who Have Completed Study TKT023 or Who Are Naive to Enzyme Replacement Therapy
Status: Archived
Updated: 1/1/1970
Baylor Institute for Rehabilitation
mi
from
Dallas, TX
Replagal Enzyme Replacement Therapy for Children With Fabry Disease
An Open Label Clinical Trial of Replagal Enzyme Replacement Therapy In Children With Fabry Disease Who Have Completed Study TKT023 or Who Are Naive to Enzyme Replacement Therapy
Status: Archived
Office of Michael Cohen
mi
from
Stafford, VA
Replagal Enzyme Replacement Therapy for Children With Fabry Disease
An Open Label Clinical Trial of Replagal Enzyme Replacement Therapy In Children With Fabry Disease Who Have Completed Study TKT023 or Who Are Naive to Enzyme Replacement Therapy
Status: Archived
Updated: 1/1/1970
Office of Michael Cohen
mi
from
Stafford, VA
Study of Megakaryocytes From Patients With Abnormal Platelet Vesicles
Investigations of Megakaryocytes From Patients With Abnormal Platelet Vesicles
Status: Archived
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Study of Megakaryocytes From Patients With Abnormal Platelet Vesicles
Investigations of Megakaryocytes From Patients With Abnormal Platelet Vesicles
Status: Archived
Updated: 1/1/1970
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma
A Clinical Trial Evaluating I131-Tositumomab (Anti-CD20) With Escalating Doses of Fludarabine Followed by Autologous or Syngeneic Stem Cell Transplantation for Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma in Patients 60 Years of Age and Older
Status: Archived
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma
A Clinical Trial Evaluating I131-Tositumomab (Anti-CD20) With Escalating Doses of Fludarabine Followed by Autologous or Syngeneic Stem Cell Transplantation for Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma in Patients 60 Years of Age and Older
Status: Archived
Updated: 1/1/1970
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
NK Cell Transplantation for AML
Pilot Study Of Haplo-Identical Natural Killer Cell Transplantation For Acute Myeloid Leukemia
Status: Archived
St. Jude Childrens Research Hosp, Memphis
mi
from
Memphis, TN
NK Cell Transplantation for AML
Pilot Study Of Haplo-Identical Natural Killer Cell Transplantation For Acute Myeloid Leukemia
Status: Archived
Updated: 1/1/1970
St. Jude Childrens Research Hosp, Memphis
mi
from
Memphis, TN
Granulocyte Colony Stimulating Factor (G-CSF) for Bone Marrow Transplant (BMT)
Pilot Study of Using Granulocyte Colony Stimulating Factor-Primed Bone Marrow in Histocompatible Sibling Allogeneic Bone Marrow Transplantation for Patients With Hematologic Malignancies and Non-Malignancies
Status: Archived
Children's Healthcare of Atlanta at Egleston - Pediatric Cardiac Intensive Care Unit
mi
from
Atlanta, GA
Granulocyte Colony Stimulating Factor (G-CSF) for Bone Marrow Transplant (BMT)
Pilot Study of Using Granulocyte Colony Stimulating Factor-Primed Bone Marrow in Histocompatible Sibling Allogeneic Bone Marrow Transplantation for Patients With Hematologic Malignancies and Non-Malignancies
Status: Archived
Updated: 1/1/1970
Children's Healthcare of Atlanta at Egleston - Pediatric Cardiac Intensive Care Unit
mi
from
Atlanta, GA
Oxandrolone for the Treatment of Bone Marrow Aplasia in Fanconi Anemia
A Pilot Trial of Oxandrolone for the Treatment of Bone Marrow Aplasia in Patients With Fanconi Anemia
Status: Archived
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Oxandrolone for the Treatment of Bone Marrow Aplasia in Fanconi Anemia
A Pilot Trial of Oxandrolone for the Treatment of Bone Marrow Aplasia in Patients With Fanconi Anemia
Status: Archived
Updated: 1/1/1970
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Compassionate Use of Deferiprone for Patients With Thalassemia and Iron-Induced Heart Disease
Compassionate Use of Deferiprone in Patients With Thalassemia and Iron-Induced Heart Disease
Status: Archived
Saint Peter's University Hospital
mi
from
New Brunswick, NJ
Compassionate Use of Deferiprone for Patients With Thalassemia and Iron-Induced Heart Disease
Compassionate Use of Deferiprone in Patients With Thalassemia and Iron-Induced Heart Disease
Status: Archived
Updated: 1/1/1970
Saint Peter's University Hospital
mi
from
New Brunswick, NJ
UCN-01 and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes
A Phase 1 Study of UCN-01 in Combination With Perifosine in Patients With Relapsed and Refractory Acute Leukemias and High Risk MDS
Status: Archived
Greenebaum Cancer Center - University of Maryland
mi
from
Baltimore, MD
UCN-01 and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes
A Phase 1 Study of UCN-01 in Combination With Perifosine in Patients With Relapsed and Refractory Acute Leukemias and High Risk MDS
Status: Archived
Updated: 1/1/1970
Greenebaum Cancer Center - University of Maryland
mi
from
Baltimore, MD
UCN-01 and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes
A Phase 1 Study of UCN-01 in Combination With Perifosine in Patients With Relapsed and Refractory Acute Leukemias and High Risk MDS
Status: Archived
Abamson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
UCN-01 and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes
A Phase 1 Study of UCN-01 in Combination With Perifosine in Patients With Relapsed and Refractory Acute Leukemias and High Risk MDS
Status: Archived
Updated: 1/1/1970
Abamson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma
A Pilot, Phase-I Trial of Rabbit Anti-Thymocyte Globulin (rATG, Thymoglobulinâ„¢) in Combination With Rapamycin in Relapsed Multiple Myeloma (MM)
Status: Archived
James P. Wilmot Cancer Center, University of Rochester
mi
from
Rochester, NY
Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma
A Pilot, Phase-I Trial of Rabbit Anti-Thymocyte Globulin (rATG, Thymoglobulinâ„¢) in Combination With Rapamycin in Relapsed Multiple Myeloma (MM)
Status: Archived
Updated: 1/1/1970
James P. Wilmot Cancer Center, University of Rochester
mi
from
Rochester, NY
Clinical Evaluations and Laboratory Studies in Patients With Chronic Graft-Versus-Host Disease Who Have Undergone a Previous Donor Stem Cell Transplant
Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Disease
Status: Archived
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Clinical Evaluations and Laboratory Studies in Patients With Chronic Graft-Versus-Host Disease Who Have Undergone a Previous Donor Stem Cell Transplant
Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Disease
Status: Archived
Updated: 1/1/1970
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Clinical Evaluations and Laboratory Studies in Patients With Chronic Graft-Versus-Host Disease Who Have Undergone a Previous Donor Stem Cell Transplant
Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Disease
Status: Archived
Hackensack Univeristy Medical Center
mi
from
Hackensack, NJ
Clinical Evaluations and Laboratory Studies in Patients With Chronic Graft-Versus-Host Disease Who Have Undergone a Previous Donor Stem Cell Transplant
Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Disease
Status: Archived
Updated: 1/1/1970
Hackensack Univeristy Medical Center
mi
from
Hackensack, NJ
BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
A Phase I Study to Assess The Safety and Pharmacokinetics of BB-10901 (huN901-DM1) Given as an Intravenous Infusion Weekly for Two Consecutive Weeks Every Three Weeks to Subjects With Relapsed and Relapsed Refractory CD56-Positive Multiple Myeloma
Status: Archived
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
A Phase I Study to Assess The Safety and Pharmacokinetics of BB-10901 (huN901-DM1) Given as an Intravenous Infusion Weekly for Two Consecutive Weeks Every Three Weeks to Subjects With Relapsed and Relapsed Refractory CD56-Positive Multiple Myeloma
Status: Archived
Updated: 1/1/1970
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
A Phase I Study to Assess The Safety and Pharmacokinetics of BB-10901 (huN901-DM1) Given as an Intravenous Infusion Weekly for Two Consecutive Weeks Every Three Weeks to Subjects With Relapsed and Relapsed Refractory CD56-Positive Multiple Myeloma
Status: Archived
University of California at San Francisco (UCSF)
mi
from
San Francisco, CA
BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
A Phase I Study to Assess The Safety and Pharmacokinetics of BB-10901 (huN901-DM1) Given as an Intravenous Infusion Weekly for Two Consecutive Weeks Every Three Weeks to Subjects With Relapsed and Relapsed Refractory CD56-Positive Multiple Myeloma
Status: Archived
Updated: 1/1/1970
University of California at San Francisco (UCSF)
mi
from
San Francisco, CA
BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
A Phase I Study to Assess The Safety and Pharmacokinetics of BB-10901 (huN901-DM1) Given as an Intravenous Infusion Weekly for Two Consecutive Weeks Every Three Weeks to Subjects With Relapsed and Relapsed Refractory CD56-Positive Multiple Myeloma
Status: Archived
Dana-Farber at Faulkner Hospital
mi
from
Boston, MA
BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
A Phase I Study to Assess The Safety and Pharmacokinetics of BB-10901 (huN901-DM1) Given as an Intravenous Infusion Weekly for Two Consecutive Weeks Every Three Weeks to Subjects With Relapsed and Relapsed Refractory CD56-Positive Multiple Myeloma
Status: Archived
Updated: 1/1/1970
Dana-Farber at Faulkner Hospital
mi
from
Boston, MA
BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
A Phase I Study to Assess The Safety and Pharmacokinetics of BB-10901 (huN901-DM1) Given as an Intravenous Infusion Weekly for Two Consecutive Weeks Every Three Weeks to Subjects With Relapsed and Relapsed Refractory CD56-Positive Multiple Myeloma
Status: Archived
University of Medicine and Dentistry - Robert Wood Johnson University Hospital
mi
from
New Brunswick, NJ
BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
A Phase I Study to Assess The Safety and Pharmacokinetics of BB-10901 (huN901-DM1) Given as an Intravenous Infusion Weekly for Two Consecutive Weeks Every Three Weeks to Subjects With Relapsed and Relapsed Refractory CD56-Positive Multiple Myeloma
Status: Archived
Updated: 1/1/1970
University of Medicine and Dentistry - Robert Wood Johnson University Hospital
mi
from
New Brunswick, NJ
BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
A Phase I Study to Assess The Safety and Pharmacokinetics of BB-10901 (huN901-DM1) Given as an Intravenous Infusion Weekly for Two Consecutive Weeks Every Three Weeks to Subjects With Relapsed and Relapsed Refractory CD56-Positive Multiple Myeloma
Status: Archived
Roswell Park Cancer Center Institute
mi
from
Buffalo, NY
BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
A Phase I Study to Assess The Safety and Pharmacokinetics of BB-10901 (huN901-DM1) Given as an Intravenous Infusion Weekly for Two Consecutive Weeks Every Three Weeks to Subjects With Relapsed and Relapsed Refractory CD56-Positive Multiple Myeloma
Status: Archived
Updated: 1/1/1970
Roswell Park Cancer Center Institute
mi
from
Buffalo, NY
BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
A Phase I Study to Assess The Safety and Pharmacokinetics of BB-10901 (huN901-DM1) Given as an Intravenous Infusion Weekly for Two Consecutive Weeks Every Three Weeks to Subjects With Relapsed and Relapsed Refractory CD56-Positive Multiple Myeloma
Status: Archived
St. Vincent's Hospital
mi
from
Los Angeles, CA
BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
A Phase I Study to Assess The Safety and Pharmacokinetics of BB-10901 (huN901-DM1) Given as an Intravenous Infusion Weekly for Two Consecutive Weeks Every Three Weeks to Subjects With Relapsed and Relapsed Refractory CD56-Positive Multiple Myeloma
Status: Archived
Updated: 1/1/1970
St. Vincent's Hospital
mi
from
Los Angeles, CA
A Comparison of Sequential Compression Devices and Foot Pumps in the Obstetric Population
Study of Patient Compliance and Comfort Using Sequential Compression Devices and Foot Pumps for DVT Prevention
Status: Archived
Johns Hopkins Hosp
mi
from
Baltimore, MD
A Comparison of Sequential Compression Devices and Foot Pumps in the Obstetric Population
Study of Patient Compliance and Comfort Using Sequential Compression Devices and Foot Pumps for DVT Prevention
Status: Archived
Updated: 1/1/1970
Johns Hopkins Hosp
mi
from
Baltimore, MD
A Comparison of Sequential Compression Devices and Foot Pumps in the Obstetric Population
Study of Patient Compliance and Comfort Using Sequential Compression Devices and Foot Pumps for DVT Prevention
Status: Archived
Johns Hopkins at Greenspring Station Pavilion II
mi
from
Lutherville, MD
A Comparison of Sequential Compression Devices and Foot Pumps in the Obstetric Population
Study of Patient Compliance and Comfort Using Sequential Compression Devices and Foot Pumps for DVT Prevention
Status: Archived
Updated: 1/1/1970
Johns Hopkins at Greenspring Station Pavilion II
mi
from
Lutherville, MD
Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving Adriamycin And Ifosfamide
An Open-label, Dose Ranging Study to Assess the Safety, Efficacy, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist (Eltrombopag) Administered to Subjects Receiving Adriamycin and Ifosfamide (AI) Regimen
Status: Archived
GSK Investigational Site
mi
from
Anaheim, CA
Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving Adriamycin And Ifosfamide
An Open-label, Dose Ranging Study to Assess the Safety, Efficacy, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist (Eltrombopag) Administered to Subjects Receiving Adriamycin and Ifosfamide (AI) Regimen
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Anaheim, CA
Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving Adriamycin And Ifosfamide
An Open-label, Dose Ranging Study to Assess the Safety, Efficacy, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist (Eltrombopag) Administered to Subjects Receiving Adriamycin and Ifosfamide (AI) Regimen
Status: Archived
GSK Investigational Site
mi
from
Philadelphia, PA
Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving Adriamycin And Ifosfamide
An Open-label, Dose Ranging Study to Assess the Safety, Efficacy, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist (Eltrombopag) Administered to Subjects Receiving Adriamycin and Ifosfamide (AI) Regimen
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Philadelphia, PA
Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving Adriamycin And Ifosfamide
An Open-label, Dose Ranging Study to Assess the Safety, Efficacy, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist (Eltrombopag) Administered to Subjects Receiving Adriamycin and Ifosfamide (AI) Regimen
Status: Archived
GSK Investigational Site
mi
from
Austin, TX
Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving Adriamycin And Ifosfamide
An Open-label, Dose Ranging Study to Assess the Safety, Efficacy, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist (Eltrombopag) Administered to Subjects Receiving Adriamycin and Ifosfamide (AI) Regimen
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Austin, TX
Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome
Phase II Study of Lenalidomide in Patients With Relapsed/Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplastic Syndrome Associated With Chromosome 5 Abnormalities
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome
Phase II Study of Lenalidomide in Patients With Relapsed/Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplastic Syndrome Associated With Chromosome 5 Abnormalities
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia
Phase II Trial of Triapine (IND # 68338, NSC #663249, 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbone) Plus Fludarabine (NSC #312887, Fludarabine Monophosphate) in Adults With Aggressive Myeloproliferative Disorders (MPDs) Including Chronic Myelomonocytic Leukemia (CMML) and Chronic Myelogenous Leukemia in Accelerated Phase (CML-AP) or Blast Crisis (CML-BC)
Status: Archived
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia
Phase II Trial of Triapine (IND # 68338, NSC #663249, 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbone) Plus Fludarabine (NSC #312887, Fludarabine Monophosphate) in Adults With Aggressive Myeloproliferative Disorders (MPDs) Including Chronic Myelomonocytic Leukemia (CMML) and Chronic Myelogenous Leukemia in Accelerated Phase (CML-AP) or Blast Crisis (CML-BC)
Status: Archived
Updated: 1/1/1970
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding
Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding
Status: Archived
Med College of Georgia
mi
from
Augusta, GA
Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding
Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding
Status: Archived
Updated: 1/1/1970
Med College of Georgia
mi
from
Augusta, GA
Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding
Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding
Status: Archived
Umass Memorial Medical Center
mi
from
Worcester, MA
Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding
Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding
Status: Archived
Updated: 1/1/1970
Umass Memorial Medical Center
mi
from
Worcester, MA
Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding
Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding
Status: Archived
Northport VA Medical Center
mi
from
Northport, NY
Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding
Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding
Status: Archived
Updated: 1/1/1970
Northport VA Medical Center
mi
from
Northport, NY
Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies
Gemcitabine Combined With Busulfan and Melphalan, With Hematopoietic Cell Transplantation, for Patients With Poor-prognosis Advanced Lymphoid Malignancies
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies
Gemcitabine Combined With Busulfan and Melphalan, With Hematopoietic Cell Transplantation, for Patients With Poor-prognosis Advanced Lymphoid Malignancies
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis
A Pilot Dose-Finding and Pharmacokinetic Study of Fondaparinux in Children With Deep Vein Thrombosis or Heparin-Induced Thrombocytopenia
Status: Archived
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis
A Pilot Dose-Finding and Pharmacokinetic Study of Fondaparinux in Children With Deep Vein Thrombosis or Heparin-Induced Thrombocytopenia
Status: Archived
Updated: 1/1/1970
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis
A Pilot Dose-Finding and Pharmacokinetic Study of Fondaparinux in Children With Deep Vein Thrombosis or Heparin-Induced Thrombocytopenia
Status: Archived
Children's Hospital
mi
from
Pittsburgh, PA
Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis
A Pilot Dose-Finding and Pharmacokinetic Study of Fondaparinux in Children With Deep Vein Thrombosis or Heparin-Induced Thrombocytopenia
Status: Archived
Updated: 1/1/1970
Children's Hospital
mi
from
Pittsburgh, PA
Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis
A Pilot Dose-Finding and Pharmacokinetic Study of Fondaparinux in Children With Deep Vein Thrombosis or Heparin-Induced Thrombocytopenia
Status: Archived
Nationwide Children's Hospital in Columbus
mi
from
Columbus, OH
Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis
A Pilot Dose-Finding and Pharmacokinetic Study of Fondaparinux in Children With Deep Vein Thrombosis or Heparin-Induced Thrombocytopenia
Status: Archived
Updated: 1/1/1970
Nationwide Children's Hospital in Columbus
mi
from
Columbus, OH
Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis
A Pilot Dose-Finding and Pharmacokinetic Study of Fondaparinux in Children With Deep Vein Thrombosis or Heparin-Induced Thrombocytopenia
Status: Archived
Texas Children's Hospital - Feigin Center
mi
from
Houston, TX
Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis
A Pilot Dose-Finding and Pharmacokinetic Study of Fondaparinux in Children With Deep Vein Thrombosis or Heparin-Induced Thrombocytopenia
Status: Archived
Updated: 1/1/1970
Texas Children's Hospital - Feigin Center
mi
from
Houston, TX
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Oncotherapeutics
mi
from
West Hollywood, CA
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Updated: 1/1/1970
Oncotherapeutics
mi
from
West Hollywood, CA
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Rocky Mountain Cancer Center
mi
from
Denver, CO
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Updated: 1/1/1970
Rocky Mountain Cancer Center
mi
from
Denver, CO
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Norwalk Hospital
mi
from
Norwalk, CT
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Updated: 1/1/1970
Norwalk Hospital
mi
from
Norwalk, CT
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Montefiore Medical Center
mi
from
Bronx, NY
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)
Status: Archived
Updated: 1/1/1970
Montefiore Medical Center
mi
from
Bronx, NY